Abstract

PI3K signalling regulates several cellular activities, including growth and apoptosis.1 Therefore, inhibition of PI3K presented an intriguing and novel therapeutic avenue to treat several haematological malignancies, such as chronic lymphocytic leukaemia, follicular lymphoma, and marginal zone lymphoma. Given the paucity of novel treatments for these malignancies in the relapsed and refractory settings, there was considerable interest when the first PI3K inhibitor, idelalisib, was approved in 2014.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call